ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0GlobeNewsWire • 06/26/23
ReShape Lifesciences® to Participate in Investor and Industry Conferences in JuneGlobeNewsWire • 06/14/23
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/23
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate UpdateGlobeNewsWire • 05/11/23
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 DiabetesGlobeNewsWire • 04/27/23
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/25/23
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-MarketGlobeNewsWire • 04/20/23
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon SystemGlobeNewsWire • 04/11/23
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference CallGlobeNewsWire • 03/29/23
ReShape Lifesciences Announces Formation of International Scientific Advisory BoardGlobeNewsWire • 03/23/23
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate UpdateGlobeNewsWire • 03/22/23
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public OfferingGlobeNewsWire • 02/08/23
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public OfferingGlobeNewsWire • 02/06/23
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022GlobeNewsWire • 12/22/22
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/14/22